Telmisartan With AmlodipinePritor/Amlodipine
Recommended CardiovascularRestrictedNot applicable line
Hypertension in a patient who is not adequately controlled with either of the drugs in the combination.
1
Submissions
2011–11
On the record
—
ICER range
Cost-min
Cost basis
Decision on record
- Meeting Mar 2011 Recommended Antihypertensive
Access path
- TGA registered · Pritor/Amlodipine
TGA label narrower than the PBS population
- Mar 2011Recommended · restricted
vs telmisartan and amlodipine as monotherapies (individual…
- PBS listing · Restricted
RecommendedDeferredNot recommended
Cost-effectiveness
Cost-minimisation analysis performed; no ICER calculated
Cost-effectiveness accepted
Decision context
Populationpatients who have trialled and failed monotherapy with either telmisartan or amlodipine
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Mar 2011 | Recommended · restricted | telmisartan and amlodipine as monotherapies (individual equivalent strengths administered separately) | — | RCT · DBP |
Similar precedents
Amlodipine Besylate With Valsartan79%Olmesartan Medoxomil With Amlodipine77%Amlodipine (As Besylate) With Valsartan And Hydrochlorothiazide76%Perindopril Arginine With Amlodipine Besylate76%Ramipril With Felodipine72%Olmesartan Medoxomil With Hydrochlorothiazide72%Valsartan With Hydrochlorothiazide71%Lercanidipine With Enalapril69%
Regulatory · TGA
Label narrower than PBS population — PBAC restricts to patients who failed monotherapy with either component drug; TGA label permits any hypertension treatment.